• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, July 1

Bristol-Myers Squibb, the global pharmaceutical and health care company, launched its antiviral drug, Baraclude (entecavir) in India for the treatment of chronic Hepatitis B. "The oral antiviral drug has been approved by the Drug Controller General of India and would be marketed by the company itself," said Dr Ajay Tiku, Medical Director, Bristol-Myers Squibb India Pvt Ltd. Priced at Rs 208 for a 0.5 mg tablet, the company has priced the drug lower in India compared with other markets. "The pricing has been done to make the medicine cost effective for patients in India," he said. Baraclude got the United States Food and Drug Administration (USFDA's) approval in March last year to be marketed in the US. It has also been launched in Australia, China, Indonesia, Philippines and Singapore this year.

More Stories on : New Products & Services | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Bristol launches Hepatitis B drug

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line